Why Am I Not Losing Weight on Ozempic? Unpacking the Reasons

Last reviewed: June 22, 2026

Last updated: June 22, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The single most common reason people feel Ozempic is not working for weight loss is that Ozempic is not a weight-loss medication. Its FDA prescribing information lists three indications, all in type 2 diabetes: improving glycemic control, reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease, and reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with chronic kidney disease. Weight reduction appears in its trials as a secondary observation, and the magnitudes recorded there are considerably smaller than the numbers circulating online — which come from different products, at different doses, in different populations. Below that, several real clinical explanations exist, and all of them are worth raising with your prescriber.

Start With What the Ozempic Trials Actually Measured

The diabetes program behind Ozempic used glycemic primary endpoints. In a 30-week double-blind monotherapy trial of 388 patients with type 2 diabetes inadequately controlled with diet and exercise, mean body weight changed by −1.2 kg on placebo, −3.8 kg on 0.5 mg and −4.7 kg on 1 mg. In a 56-week trial against sitagliptin, mean weight change was −4.2 kg and −5.5 kg on the two Ozempic doses versus −1.7 kg on sitagliptin. Against exenatide extended-release over 56 weeks, Ozempic 1 mg produced −4.8 kg versus −2.0 kg.

Those are the numbers on the label. Four to six kilograms over roughly a year, in people with type 2 diabetes, at diabetes dose ranges. If your expectation was set by a 15% or 20% figure, the shortfall may not be a treatment failure at all — it may be an expectation calibrated to a different medicine.

The Obesity Programs Used Different Products

The semaglutide product approved for chronic weight management is Wegovy, not Ozempic, and it was studied at higher doses over longer durations in people with obesity or overweight rather than diabetes. STEP 1 ran 68 weeks and reported mean weight change of −14.9% with semaglutide 2.4 mg versus −2.4% with placebo. The Wegovy label now also includes a 7.2 mg once-weekly maximum, supported by a 72-week trial in 1,407 participants reporting −18.8% at 7.2 mg, −15.5% at 2.4 mg and −3.9% on placebo.

Dose, duration, population and primary endpoint all differ. Comparing your experience on a diabetes product to a headline from an obesity program is comparing two different studies. The first useful question to ask your prescriber is simply: which product am I actually on, and what does its evidence base say I should expect?

Escalation Takes Longer Than People Expect

Semaglutide is not started at its studied maintenance dose. The labeled regimen begins at a low starting dose chosen for gastrointestinal tolerability rather than efficacy, and steps upward at intervals under a prescriber's direction. In the pivotal obesity trials, dose escalation alone consumed the first several months of a 68-week protocol.

Semaglutide's pharmacokinetics reinforce this. The elimination half-life is approximately one week, so every dose change takes weeks to reach a new steady state. Judging response at week six, or after one or two dose steps, measures the escalation schedule rather than the drug. Where you are in that sequence, and whether a change is appropriate, is a decision for the clinician managing your prescription.

Plateaus Are Physiology, Not Failure

Weight loss on any intervention slows and eventually flattens. As body mass falls, total energy expenditure falls with it, and appetite regulation shifts in the direction of defending the lost weight. This is why trial curves bend rather than continuing as straight lines, and why the endpoint of a 68-week study is not a rate you can extrapolate forward indefinitely.

The strongest illustration comes from the STEP 1 trial extension, which followed 327 participants for a further year after all treatment stopped at week 68. Mean weight loss on semaglutide 2.4 mg had been 17.3% at week 68. By week 120 — a year off treatment — participants had regained 11.6 percentage points of that loss, leaving a net 5.6% below baseline. Cardiometabolic improvements largely reverted alongside the weight. Obesity behaves like a chronic condition that is managed rather than cured, and a plateau while still on treatment is a very different thing from regain after stopping.

What the Label Rules Out as an Explanation

It is worth knowing what the evidence says is not the reason. The Ozempic label states that its efficacy was not impacted by age, gender, race, ethnicity, baseline BMI, baseline body weight, diabetes duration or level of renal function impairment. Those are the demographic factors people most often blame, and in the trial data they did not drive the result.

That narrows the field considerably. What remains is generally the things a clinician can actually look at: where you are in escalation, whether doses have been missed or interrupted by supply gaps, other prescriptions with known weight effects, untreated conditions, alcohol intake, and whether the diet-and-activity component the label describes as an adjunct is genuinely in place. None of those can be assessed from the outside.

Individual Response Varies Around the Mean

Every number quoted above is an average. Within the same trial arm, some participants lost a great deal and others lost very little, and that spread is normal for this drug class rather than a sign that something has gone wrong. A mean is a description of a population, not a promise to any individual in it.

What that means practically is that "not losing weight" is a clinical observation to bring to a prescriber, not a verdict. It may lead to a reassessment of the product, the indication, the timeline, or the surrounding plan. It may also lead to the conclusion that things are proceeding normally and the timeline was simply compressed in your head.

Frequently Asked Questions

Why am I not losing weight on Ozempic?

The most common reason is that Ozempic is approved for type 2 diabetes, not weight management, and its trials recorded weight change as a secondary outcome at diabetes dose ranges — roughly four to six kilograms over 30 to 56 weeks. Other contributors include being early in dose escalation, a normal physiological plateau, missed doses, or other medications. Your prescriber can work through which applies.

Is Ozempic supposed to cause weight loss?

Weight reduction is observed with semaglutide but it is not what Ozempic is approved for. The Ozempic label covers glycemic control in type 2 diabetes, major adverse cardiovascular event risk reduction in adults with established cardiovascular disease, and cardiorenal risk reduction in adults with chronic kidney disease. Weight change appears in the clinical studies section as a secondary measure, not as an indication.

How long does it take to see results?

Longer than most people expect, because semaglutide is not started at its maintenance dose and its elimination half-life is about one week, so each dose step takes weeks to reach steady state. In the pivotal obesity trials, escalation occupied the opening months of a 68-week protocol. Any judgment about whether your regimen is working should come from the prescriber tracking it.

Why did my weight loss stall after a few months?

Plateaus are expected. As weight falls, total energy expenditure falls with it and appetite regulation shifts toward defending the new weight, so trial curves bend rather than continuing in a straight line. A plateau while still on treatment is not the same as regain after stopping, and it does not automatically mean the medication has stopped working. Discuss it with your clinician.

What happens if I stop taking semaglutide?

The STEP 1 trial extension followed 327 participants for a year after all treatment ended at week 68. Mean weight loss had been 17.3%; by week 120 participants had regained 11.6 percentage points, leaving a net 5.6% below baseline, with cardiometabolic improvements largely reverting. That pattern is why obesity is described as a chronic condition requiring ongoing management rather than a finite course of treatment.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.